John and his team advised Diogenix in the sale of its diagnostic business to Amarantus Bioscience. Geneva, Switzerland-based DioGenix develops diagnostic tests for immune-mediated neurological diseases such as multiple sclerosis (MS). Its lead product, MSPrecise, is a next-generation sequencing assay that can identify MS at first clinical presentation. Amarantus, based in San Francisco, develops diagnostic tests in neurology and therapeutic products in neurology, psychiatry, opthamology, and regenerative medicine. DioGenix merged into Amarantus as a foundational asset of a growing neuro-diagnostics business. Amarantus now owns all rights to DioGenix’s products under development, including tests targeting neurosarcoid, neuromyelitis optica, paraneoplastic disease, and amyotrophic lateral sclerosis.
Note: This work was performed prior to joining Stout.